New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
09:11 EDTXLRN, CELGAcceleron Sotatercept has growing potential, says JMP Securities
After Acceleron (XLRN) and its partner Celgene (CELG) presented data on sotatercept in patients with end-stage renal disease, JMP Securities thinks the results suggest that the treatment's potential in anemia in hemodialysis poatients is growing. The firm reiterates a $53 price target and Outperform rating on the stock.
News For XLRN;CELG From The Last 14 Days
Check below for free stories on XLRN;CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
09:31 EDTXLRNAcceleron management to meet with JMP Securities
Subscribe for More Information
September 17, 2014
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
September 15, 2014
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
14:06 EDTXLRNAcceleron management to meet with Leerink
Subscribe for More Information
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use